Tranziger Announces Formation of Global Advisory & Development Team

LONDON and WASHINGTON -

- Formation creates a new model for enterprise value & growth in the life sciences and healthcare sectors

Tranziger Limited announced today the formation of its global advisory and business team to advise and assess companies in the life sciences and healthcare sectors to execute strategic transactions and realise and optimise value from their portfolios in these turbulent times. Tranziger Limited is headquartered in London, England, UK and has offices in Washington, DC and Edinburgh.

The Tranziger team will be attending the upcoming BioPartnering Europe conference from October 12-14 at the Queen Elizabeth Conference Centre in London.

Established in early 2009 by a group of senior, highly experienced international corporate business transactional professionals, Tranziger aims to help the managers and owners of small and mid-tier companies in the Biotechnology, Pharmaceutical, Diagnostics and Medical Technology sectors realise value in the currently challenging global economic environment. The group offers strategic transaction advisory and execution services including Mergers and Acquisitions, Corporate and Commercial Development, Corporate Partnering, technical due diligence, and strategic R&D consultancy. Tranziger also has a proprietary service for venture formation, development and commercialisation utilised by larger corporations, universities, government agencies and investment organizations.

Tranziger distinguishes itself from other groups by the fact that its team members originate from the same peer group as many of their prospective clients and deal partners, combining scientific acumen with seasoned experience at the transactional coalface. The group’s geographical reach extends to Europe, North America and Asia Pacific, offering scope for a wider base of creative solutions and deal potential.

Dr. V. Paul Gerskowitch, Executive Chairman of Tranziger, said, “The global downturn has caused an intense reevaluation of business models and priorities. Very many newer spinout and mid-tier companies will struggle to survive, doomed by an inability to raise sufficient capital, partner or grow organically. At the same time, larger companies are increasingly staking claims earlier in all phases of technology development.”

Neil J. Campbell, Managing Director, North America, said, “As investors focus ever more on those companies with quality data and revenue potential, the life science and healthcare sectors will likely selectively consolidate around those with top quality offerings. Increasingly, there will be a shift away from financial engineers to business builders. This will be brought about by the rise of so-called third age entrepreneurs and the need to derive more value from technology portfolios, thus spreading the risk. Proactive portfolio management and product/technology life cycle management, achieved via Tranziger’s Portfolio Partnering model, will become an ever more urgent and value-driving activity for companies.”

About Tranziger Limited

Tranziger was established in 2009 by a group of senior, highly experienced international corporate business transactional professionals. Tranziger aims to help the managers and owners of small and mid-sized companies in the Biotechnology, Pharmaceutical, Diagnostics and Medical Technology sectors realise value in the currently challenging global economic environment. The group offers strategic transaction advisory and execution services including Mergers and Acquisitions, Corporate and Commercial Development, Corporate Partnering, technical due diligence, and strategic R&D consultancy. Tranziger also has a proprietary service for venture formation, development and commercialization utilised by larger corporations, universities, government agencies and investment organizations. Further information about Tranziger can be found at www.tranziger.com.

Contact: Tranziger, Limited +44-20-8663-3472 Dr. Paul Gerskowitch, Executive Chairman gerskowitch@tranziger.com or Neil Campbell, Managing Director North American Operations +1-301-792 4345 campbell@tranziger.com Tiberend Strategic Advisors, Inc. +1-212-827-0020 Andrew Mielach amielach@tiberendstrategicadvisors.com or Farrell Denby fdenby@tiberendstrategicadvisors.com

Source: Tranziger Limited

Tranziger, Limited, +44-20-8663-3472, Dr. Paul Gerskowitch, Executive Chairman, gerskowitch at tranziger.com, or Neil Campbell, Managing Director North American Operations, +1-301-792-4345, campbell at tranziger.com; or Tiberend Strategic Advisors, Inc., +1-212-827-0020, Andrew Mielach, amielach at tiberendstrategicadvisors.com, or Farrell Denby, fdenby at tiberendstrategicadvisors.com